{"id":451,"date":"2026-08-27T10:31:11","date_gmt":"2026-08-27T10:31:11","guid":{"rendered":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/"},"modified":"2026-08-28T07:31:46","modified_gmt":"2026-08-28T07:31:46","slug":"cagrilintide-amylin-analog-phase-2-evidence","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/pt-br\/cagrilintide-amylin-analog-phase-2-evidence\/","title":{"rendered":"Cagrilintide como um an\u00e1logo de amilina de a\u00e7\u00e3o prolongada: lendo as evid\u00eancias da fase 2"},"content":{"rendered":"<p class=\"pim-standfirst wp-block-paragraph\">Cagrilintide \u00e9 um an\u00e1logo da amilina de a\u00e7\u00e3o prolongada desenvolvido para estudo uma vez por semana. Pertence a uma categoria de sinaliza\u00e7\u00e3o diferente dos agonistas do receptor GLP-1, embora programas cl\u00ednicos posteriores tenham avaliado a cagrilintida juntamente com a semaglutida.<\/p><div class=\"wp-block-group pim-key-takeaways\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 class=\"wp-block-heading\">Principais conclus\u00f5es<\/h2><ul class=\"wp-block-list\"><li>Cagrilintide \u00e9 um an\u00e1logo da amilina; semaglutida \u00e9 um agonista do receptor GLP-1.<\/li><li>A evid\u00eancia 2 de fase de agente \u00fanico deve ser diferenciada dos ensaios posteriores de combina\u00e7\u00e3o CagriSema.<\/li><li>De acordo com as informa\u00e7\u00f5es revisadas do FDA, o cagrilintide n\u00e3o \u00e9 um componente de um medicamento aprovado pelo FDA.<\/li><\/ul><\/div><\/div><figure class=\"wp-block-image size-full pim-article-figure\"><img loading=\"lazy\" decoding=\"async\" width=\"1672\" height=\"941\" src=\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/metabolic-peptide-receptor-research.png\" alt=\"Pesquisador revisando tr\u00eas vias de sinaliza\u00e7\u00e3o de receptores pept\u00eddicos em um laborat\u00f3rio de biologia molecular\" class=\"wp-image-442\" srcset=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/metabolic-peptide-receptor-research.png 1672w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/metabolic-peptide-receptor-research-300x169.png 300w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/metabolic-peptide-receptor-research-1024x576.png 1024w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/metabolic-peptide-receptor-research-768x432.png 768w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/metabolic-peptide-receptor-research-1536x864.png 1536w\" sizes=\"auto, (max-width: 1672px) 100vw, 1672px\" \/><figcaption class=\"wp-element-caption\">Ilustra\u00e7\u00e3o original de laborat\u00f3rio da pesquisa de receptores de pept\u00eddeos; os caminhos s\u00e3o conceituais e n\u00e3o cont\u00eam dados de ensaio.<\/figcaption><\/figure><h2 class=\"wp-block-heading\">Por que a amilina \u00e9 um caminho de pesquisa distinto<\/h2><p class=\"wp-block-paragraph\">A amilina \u00e9 co-secretada com a insulina e participa da sinaliza\u00e7\u00e3o relacionada aos nutrientes. Cagrilintide foi projetado para exposi\u00e7\u00e3o prolongada em rela\u00e7\u00e3o \u00e0 amilina nativa. A farmacologia do receptor e o design molecular n\u00e3o s\u00e3o intercambi\u00e1veis \u200b\u200bcom GLP-1, GIP ou agonismo do receptor de glucagon.<\/p><h2 class=\"wp-block-heading\">O que a fase de teste 2 contribui<\/h2><p class=\"wp-block-paragraph\">O estudo de fase randomizada 2 comparou m\u00faltiplos grupos de dose de cagrilintide com placebo e um comparador ativo em adultos com sobrepeso ou obesidade. Ele avaliou a mudan\u00e7a no peso corporal e na seguran\u00e7a durante o per\u00edodo do estudo. O artigo apoiou o desenvolvimento cont\u00ednuo, mas n\u00e3o tornou a cagrilintida um medicamento aprovado.<\/p><p class=\"wp-block-paragraph\">Ao resumir o ensaio, os detalhes \u00fateis s\u00e3o popula\u00e7\u00e3o, randomiza\u00e7\u00e3o, comparador, dura\u00e7\u00e3o, desfecho prim\u00e1rio e padr\u00e3o de eventos adversos. Copiar uma percentagem m\u00e1xima sem esses qualificadores n\u00e3o \u00e9 uma revis\u00e3o de evid\u00eancia adequada.<\/p><div class=\"wp-block-group pim-evidence-table\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><div class=\"pim-evidence-row\"><strong>Classe de mol\u00e9cula<\/strong><span>An\u00e1logo de amilina de a\u00e7\u00e3o prolongada<\/span><\/div><div class=\"pim-evidence-row\"><strong>Tipo de evid\u00eancia<\/strong><span>Ensaio humano de fase randomizada 2<\/span><\/div><div class=\"pim-evidence-row\"><strong>Limite de desenvolvimento<\/strong><span>Investigacional; n\u00e3o \u00e9 equivalente a produtos de semaglutida aprovados<\/span><\/div><\/div><\/div><h2 class=\"wp-block-heading\">Agente \u00fanico n\u00e3o \u00e9 igual ao CagriSema<\/h2><p class=\"wp-block-paragraph\">CagriSema refere-se \u00e0 coadministra\u00e7\u00e3o de cagrilintida e semaglutida em programas cl\u00ednicos espec\u00edficos. Os resultados dessa combina\u00e7\u00e3o n\u00e3o podem ser apresentados como resultados apenas de cagrilintida, e nenhum conjunto de dados valida uma mistura fornecida de forma independente, a menos que a equival\u00eancia e a qualidade do produto sejam estabelecidas.<\/p>","protected":false},"excerpt":{"rendered":"<p>Um guia baseado na fonte para a farmacologia do receptor de amilina da cagrilintida, desenho do ensaio de fase 2 e o limite entre evid\u00eancia de agente \u00fanico e combina\u00e7\u00e3o.<\/p>","protected":false},"author":1,"featured_media":621,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"320","pim_article_type":"Clinical evidence review","pim_evidence_level":"Randomized phase 2 human trial; investigational single-agent context","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-27","pim_editorial_note":"Source-checked against the linked primary or authoritative records on 2026-08-27. This is an evidence summary, not independent peer review, medical advice or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"Once-weekly cagrilintide in people with overweight and obesity \u2014 phase 2 trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34798060\/\",\"note\":\"Primary randomized phase 2 record; PMID 34798060.\"},{\"title\":\"FDA information on cagrilintide and other unapproved GLP-1-related products\",\"url\":\"https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss\",\"note\":\"Current regulatory-status boundary.\"}]","footnotes":""},"categories":[18],"tags":[],"class_list":["post-451","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-reviews"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Cagrilintide as a Long-Acting Amylin Analog: Reading the Phase 2 Evidence - NHD<\/title>\n<meta name=\"description\" content=\"A source-grounded guide to cagrilintide\u2019s amylin-receptor pharmacology, phase 2 trial design and the boundary between single-agent and combination evidence.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/pt-br\/cagrilintide-amylin-analog-phase-2-evidence\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cagrilintide as a Long-Acting Amylin Analog: Reading the Phase 2 Evidence\" \/>\n<meta property=\"og:description\" content=\"A source-grounded guide to cagrilintide\u2019s amylin-receptor pharmacology, phase 2 trial design and the boundary between single-agent and combination evidence.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/pt-br\/cagrilintide-amylin-analog-phase-2-evidence\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-27T10:31:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:31:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Cagrilintide as a Long-Acting Amylin Analog: Reading the Phase 2 Evidence\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/\"},\"wordCount\":284,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp\",\"articleSection\":[\"Evidence Reviews\"],\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/\",\"name\":\"Cagrilintide as a Long-Acting Amylin Analog: Reading the Phase 2 Evidence - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"description\":\"A source-grounded guide to cagrilintide\u2019s amylin-receptor pharmacology, phase 2 trial design and the boundary between single-agent and combination evidence.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cagrilintide as a Long-Acting Amylin Analog: Reading the Phase 2 Evidence\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/pt-br\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cagrilintide como um an\u00e1logo de amilina de a\u00e7\u00e3o prolongada: lendo as evid\u00eancias da fase 2 - NHD","description":"Um guia baseado na fonte para a farmacologia do receptor de amilina da cagrilintida, desenho do ensaio de fase 2 e o limite entre evid\u00eancia de agente \u00fanico e combina\u00e7\u00e3o.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/pt-br\/cagrilintide-amylin-analog-phase-2-evidence\/","og_locale":"pt_BR","og_type":"article","og_title":"Cagrilintide as a Long-Acting Amylin Analog: Reading the Phase 2 Evidence","og_description":"A source-grounded guide to cagrilintide\u2019s amylin-receptor pharmacology, phase 2 trial design and the boundary between single-agent and combination evidence.","og_url":"https:\/\/nhdbio.com\/pt-br\/cagrilintide-amylin-analog-phase-2-evidence\/","og_site_name":"NHD","article_published_time":"2026-08-27T10:31:11+00:00","article_modified_time":"2026-08-28T07:31:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Escrito por":"NHD Technical Team","Est. tempo de leitura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Cagrilintide as a Long-Acting Amylin Analog: Reading the Phase 2 Evidence","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:31:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/"},"wordCount":284,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp","articleSection":["Evidence Reviews"],"inLanguage":"pt-BR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/","url":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/","name":"Cagrilintide como um an\u00e1logo de amilina de a\u00e7\u00e3o prolongada: lendo as evid\u00eancias da fase 2 - NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:31:46+00:00","description":"Um guia baseado na fonte para a farmacologia do receptor de amilina da cagrilintida, desenho do ensaio de fase 2 e o limite entre evid\u00eancia de agente \u00fanico e combina\u00e7\u00e3o.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Cagrilintide as a Long-Acting Amylin Analog: Reading the Phase 2 Evidence"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Mat\u00e9rias-primas pept\u00eddicas e s\u00edntese personalizada","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"Equipe T\u00e9cnica NHD","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"A equipe t\u00e9cnica NHD mant\u00e9m documenta\u00e7\u00e3o de cat\u00e1logo de uso em pesquisa e resumos de evid\u00eancias. Os artigos revisados \u200b\u200bvinculam-se a artigos revisados \u200b\u200bpor pares, registros de ensaios e registros regulat\u00f3rios, ret\u00eam resultados nulos e limita\u00e7\u00f5es de estudos e distinguem interven\u00e7\u00f5es publicadas de materiais de cat\u00e1logo. O desenho assistido por AI pode ser usado para estrutura; os links de origem e os limites das evid\u00eancias permanecem vis\u00edveis. Este trabalho n\u00e3o \u00e9 uma revis\u00e3o independente por pares ou aconselhamento m\u00e9dico.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/pt-br\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts\/451","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/comments?post=451"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts\/451\/revisions"}],"predecessor-version":[{"id":520,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts\/451\/revisions\/520"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/media\/621"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/media?parent=451"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/categories?post=451"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/tags?post=451"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}